Christian Angermayer, the chairman of Germany-based biopharmaceutical company atai Life Sciences (ATAI) announced today that the firm would develop its own bitcoin treasury strategy.

“In an era of persistent inflation and volatile markets, I find myself asking an important question for biotech companies looking to preserve and optimize the capital they have: Could allocating a portion of treasury cash to bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success,” Angermayer wrote on Substack.

The company will initially invest $5 million in bitcoin, Angermayer said, while holding enough cash, short-term securities and public equity for operational expenses into 2027.
#TUT Price Rise#
#Crypto ETFs Under Application#

OWN12.52%

BTC-0.46%

The content is for reference only, not a solicitation or offer. No investment, tax, or legal advice provided. See Disclaimer for more risks disclosure.

12 Likes